Reuters logo
BRIEF-Inovio Zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study
June 7, 2017 / 1:29 PM / in 5 months

BRIEF-Inovio Zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study

June 7 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study

* Inovio - ‍results from previous preclinical study with gls-5700 demonstrated single dose of vaccine protected 100% of mice from infection, brain damage death after exposure to virus​‍​

* Inovio pharmaceuticals inc - ‍a single dose of inovio’s zika vaccine also provided 100% protection from virus in a study of non-human primates.​

* Inovio pharmaceuticals inc - ‍inovio’s second phase i study of 160 subjects in puerto rico (zika-002) will complete enrollment this month.​

* Inovio pharmaceuticals - ‍new preclinical data suggests that zika vaccine may represent an opportunity to limit potential for sexual transmission of virus​

* Inovio pharmaceuticals- ‍in addition to ongoing zika-001 and 002 clinical studies, planning for a larger phase 2 study in efforts to bring zika vaccine to patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below